HOFFMAN ESTATES, IL, June 19, 2018 (GLOBE NEWSWIRE) -- Wellness Center USA, Inc. (OTCQB: WCUI), today announced that its wholly‐owned subsidiary, Psoria-Shield, Inc. (PSI), has sold and delivered another Psoria-Light® unit (PL 1000) to a prominent healthcare organization located in Chicago, IL.
The sale builds on an ongoing multi-unit arrangement between PSI and the healthcare organization, which aims to utilize the Psoria-Light’s leading-edge UV LED phototherapy technology to treat patients suffering from autoimmune skin diseases such as psoriasis, eczema, and vitiligo.
Per the arrangement, units will be supplied to individual clinics on a scheduled basis predicated upon in-service and educational program coordination. The objective is to have all selected hospital system clinics equipped with the PL 1000 as medical staff become properly trained to treat previously identified skin conditions.
“Our collaboration gives us a unique opportunity and platform to help thousands of people seeking skin treatment,” stated John Yorke, Managing Director of PSI. “This organization is at the forefront of leading-edge treatments for primary and secondary care patients. We look forward to working closely with them on this endeavor,” continued Yorke.
Psoria-Light® is built on an established clinical modality, utilizes the most advanced LED technology available today, and incorporates innovative features born from a collaboration of opinion-leading medical doctors, biomedical engineers, and scientists.
About Wellness Center USA, Inc.
Wellness Center USA, Inc. (www.wellnesscenterusa.com) is a hybrid healthcare company that combines best in class technologies, software, devices, providers, protocols, goods, and services. It was created to address important healthcare and wellness needs via breakthrough solutions, all centered around the “well‐being of the body and mind”. Wellness Center USA, Inc. is the parent company of two businesses reporting consolidated: Stealth Mark and Psoria‐Shield.
Safe Harbor Statement:
Certain statements and projections contained in this presentation that are not statements or financial results of historical fact constitute forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements and projections include statements regarding any proposed exchange transactions, the anticipated closing date of such transactions and future results following a closing of the transactions. Forward‐looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words like “believe,” “expect,” “anticipate,” “pending”, “estimate,” and “intend” or future or conditional vrbs such as “will,” “would,” “should,” “could,” or “may.” While it is not possible to identify all factors, risks and uncertainties that might relate to, affect or arise from the proposed transactions and plans which might cause actual results to differ materially from expected results, such factors, risks and uncertainties include delays in completing the transactions, difficulties in integrating operations following the transactions, difficulties in manufacturing and delivering products, potential market rejection of products or services, increased competitive pressures, changes in general economic conditions, legislative and regulatory changes that adversely affect the business in which the parties are engaged, changes in the securities markets and other factors, risks and uncertainties disclosed from time to time in documents that the Company files with the SEC.